

REPRINT FROM MARCH 3, 2016

EMERGING COMPANY PROFILE

SNP IT ALL TOGETHER

By Karen Tkach, Staff Writer

Genomewide association studies can link SNPs to specific disease phenotypes, but the narrow scope of individual SNP studies limits their power of prediction for targeting the associated genes. **Genomics plc** is developing a computational platform that integrates disparate sets of genomic and phenotypic data to predict the good and bad outcomes of a compound's on-target effects.

The company has “the largest database of its kind that links genetic variation with health and other phenotypic outcomes,” said co-founder and director Peter Donnelly. “Most groups in the academic context doing disease studies take individuals with a particular disease and measure them genetically, and compare them with healthy individuals and look for differences. We're in the position where we know the relationship between genetic variation and many different things.” Donnelly is also director of the **Wellcome Trust Centre for Human Genetics** and a professor of statistical science at the **University of Oxford**.

He said Genomics has amassed public and “semi-public” data from about 2.7 million individuals, including SNPs and phenotypes.

The company establishes genotypes by gathering measurements of about 500,000 SNPs from individuals' genomes, then using genotype imputation — an established statistical method developed by Donnelly and his Oxford colleagues — to predict over six million additional SNPs based on genetic linkage.

In parallel, the company compiles multiple types of phenotypic information associated with SNPs, ranging from binary disease diagnoses to large sets of biomarkers.

Genomics analyzes the amassed information with a computational platform developed in-house to “exploit that multiplicity of measurements” and aid drug development in at least three ways, Donnelly said.

First, the platform can help validate disease targets. For example, the failure of **GlaxoSmithKline plc's** **PLA2G7** inhibitor darapladib in a 2014 Phase III trial for acute coronary syndrome could have been predicted by the

GENOMICS PLC, Oxford, U.K.

Technology: Computational genomic analyses for target validation and drug repositioning

Disease focus: Genomics

Clinical status: NA

Founded: 2014 by Peter Donnelly, Gil McVean, Chris Spencer and Gerton Lunter

University collaborators: **University of Oxford**, **Oxford University Hospitals NHS Foundation Trust**

Corporate partners: **Biogen Inc.**, **Eisai Co. Ltd.**, **Merck & Co. Inc.**, **Vertex Pharmaceuticals Inc.**

Number of employees: 40

Funds raised: £11 million (\$15.3 million)

Investors: **IP Group plc**, **Invesco Perpetual**, **Lansdowne Partners Ltd.**, **Woodford Investment Management LLP**

CEO: John Colenutt

Patents: Undisclosed

platform. In a post-hoc analysis, Genomics found SNPs associated with low **PLA2G7** levels did not protect individuals from heart disease, which suggested inhibiting the target would have little effect.

Second, he said, Genomics' platform can identify new opportunities for compounds that fail in one indication by whether other diseases could benefit from inhibiting the gene.

Third, the platform can de-risk targets by identifying safety issues. “You might find that if you have lower levels of gene X you get less heart disease, but if you also get more prostate cancer, the genetics is then pointing to a safety effect.”

Genomics has entered research collaborations with four pharmas on projects that include target selection, indication selection and compound repositioning, and has partnered with Oxford and **Oxford University Hospitals NHS Foundation Trust** to develop tools for a pilot phase of the 100,000 Genomes Project in the U.K. Internally, the company is developing more tools for integrating genomic, phenotype and other “-omics” data sets “to extract the most useful and relevant information” for drug discovery.

At least one other company, **Global Genomics Group LLC (G3)**, validates therapeutic targets by analyzing genomic and phenotypic information. But whereas G3 has collected data using its own protocols to build a proprietary pan-omics database of 7,500 individuals, Genomics' methods allow it to integrate and analyze data for over two million individuals from studies that used differing protocols. **■**

COMPANIES AND INSTITUTIONS MENTIONED

Genomics plc, Oxford, U.K.

Global Genomics Group LLC (G3), Richmond, Va.
GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.
Oxford University Hospitals NHS Foundation Trust, Oxford, U.K.
University of Oxford, Oxford, U.K.
Wellcome Trust Centre for Human Genetics, Oxford, U.K.

TARGETS

PLA2G7 (PAFAH; Lp-PLA2) - Lipoprotein-associated phospholipase A2

REFERENCES

Tkach, K. "**-Omics overdrive.**" **BioCentury Innovations (2016)**

BIOCENTURY PUBLICATIONS, INC.

NEWSROOM

pressreleases@biocentury.com

SAN CARLOS, CA

+1 650-595-5333; Fax: +1 650-595-5589

CHICAGO

+1 312-755-0798; Fax: +1 650-595-5589

WASHINGTON, DC

+1 202-462-9582; Fax: +1 202-667-2922

UNITED KINGDOM

+44 (0)1865-512184; Fax: +1 650-595-5589

All contents Copyright © 2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of BioCentury and its contents by current subscribers is governed by the BioCentury User Agreement and by all others is governed by the BioCentury Terms of Use, unless a written agreement to the contrary has been executed by BioCentury Publications, Inc. No part of BioCentury or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury Publications, Inc., which may be requested from Reprints/Permissions at www.biocentury.com.

Trademarks: BioCentury[®]; BCIQ[™]; The BioCentury 100[™]; Because Real Intelligence is Hard to Find[™]; and The Clear Route to ROI[™] are trademarks of BioCentury Publications, Inc.

Use of Images: Certain Images used in BioCentury Publications, Inc.'s Publications, Video Content, Websites, Services, Notices and/or Marketing Materials are licensed from Getty Images (US), Inc. Any such image of a person or object so displayed is being used for illustrative purposes only and any such person or object depicted, if any, is merely a model. For more information see "Use of Images" found under the "About Us" tab on the Homepage at www.biocentury.com.

All information provided through BioCentury Publications, Inc.'s Publications, Video and Audio Content, and Websites is gathered from sources that BioCentury believes are reliable; however, BioCentury does not guarantee the accuracy, completeness, or timeliness of such information, makes no warranties regarding such information, and is not responsible for any investment, business, tax or legal decision made or action taken in reliance upon such information.